



WuXi Biologics Receives Best IPO Award and Best Investor Relations Award 2017

Hong Kong, January 9, 2018 – **WuXi Biologics (stock code: 2269.HK)**, a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that it received the Best IPO Award and Best Investor Relations Award at the “China Financial Market Listed Companies Awards 2017” (“the Award”).

The award ceremony of the “China Financial Market Listed Companies Awards 2017” was held yesterday in Hong Kong, during which listed companies and financial organizations that enjoyed extraordinary performance in 2017 were honored. More than 100 executives of listed companies, representatives of financial institutions, political and business elites and leaders attended the event.

The Award is organized by the renowned financial magazine “Chinese Financial Market”, and the award presentation is regarded as a major annual capital market event and a crowning achievement for those in the financial industry. Since it was launched, the Award has gained the broad attention and high recognition of all different sectors in the Hong Kong society for its fair review mechanism and authoritative review committee. The aim of the Award is to strengthen the brand influence and reputation of quality companies and organizations in the global capital market, helping capture the eyes of and enhance understanding of those companies and organizations among domestic and foreign investors, to improve company communication with investors, bringing out a company’s value and raising attention on the companies, and also foster Mainland-Hong Kong economic connection and development and interaction between capital markets at home and abroad.

Since its listing on the Hong Kong capital market last June, WuXi Biologics has gained the attention of domestic and foreign investors. The two awards WuXi Biologics received at the “China Listed Companies Awards 2017” are evidence of the high recognition it enjoys for its outstanding performance in the capital market and excellent work in maintaining good investor relations, affirming its efforts on striving for better transparency and communication with the capital market and its brand influence and reputation in the market.

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our

company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

- End -

For Enquiries:

Ms. Eileen Wang
IR Senior Director
WuXi Biologics (Cayman) Inc.
Email: ir@wuxibiologics.com